XML 32 R12.htm IDEA: XBRL DOCUMENT v3.22.4
Financial Instruments
12 Months Ended
Dec. 31, 2022
Fair Value Disclosures [Abstract]  
Financial Instruments Financial Instruments
A summary of financial instruments measured at fair value was as follows (in thousands):
December 31, 2022Level 1Level 2Level 3Total
Cash equivalents:
Money market funds$10,098 $— $— $10,098 
Total assets$10,098 $ $ $10,098 
Long-term liabilities:
Contingent consideration— — (40,400)(40,400)
Total liabilities $ $ $(40,400)$(40,400)
December 31, 2021Level 1Level 2Level 3Total
Cash equivalents:
Money market funds$10,015 $— $— $10,015 
Total assets$10,015 $ $ $10,015 
Long-term liabilities:
Contingent consideration— — (49,400)(49,400)
Total liabilities$ $ $(49,400)$(49,400)
We used prices quoted from our investment advisors to determine the Level 1 valuation of our investments in money market funds. The estimated market value of all cash equivalents is equal to cost basis as there were no gross realized gains or losses on cash equivalents for the years ended December 31, 2022, 2021, and 2020.
The fair value of the contingent consideration component of the Ascyrus acquisition was updated using Level 3 inputs. See Note 3 for further discussion of the Ascyrus acquisition. Changes in fair value of Level 3 assets and liabilities are listed in the tables below (in thousands):
Contingent Consideration
Balance as of December 31, 2021$(49,400)
Change in valuation9,000 
Balance as of December 31, 2022$(40,400)